Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Tranylcypromine + Tretinoin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tranylcypromine||Parnate||Dl-Tranylcypromine||KDM1A Inhibitor 14||Parnate (tranylcypromine) is a monoamine oxidase inhibitor (MAOI) that also inhibits Kdm1a (Lsd1), which may lead to inhibition of stem cell growth through epigenetic regulation (PMID: 26748182).|
|Tretinoin||Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA||Tretinoin is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Tretinoin is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A - AFF1||acute myeloid leukemia||predicted - sensitive||Tranylcypromine + Tretinoin||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of Parnate (tranylcypromine) resulted in increased sensitivity to Tretinoin treatment in acute myeloid leukemia cells harboring a KMT2A-AFF1 fusion (also known as MLL-AF4), with inhibition of cell growth and CD11b expression in culture (Blood (2012) 120 (21): 1345.).||detail...|
|KMT2A - AFF4||leukemia||predicted - sensitive||Tranylcypromine + Tretinoin||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of Parnate (tranylcypromine) resulted in increased sensitivity to Tretinoin treatment in a murine leukemic cell line harboring a KMT2A-AFF4 fusion (also known as MLL-AF5q31), with inhibition of cell growth and CD11b expression in culture (Blood (2012) 120 (21): 1345.).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02273102||Phase I||Tranylcypromine + Tretinoin||Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA)||Completed||USA||0|